Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RDNT
RDNT logo

RDNT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
70.415
Open
69.760
VWAP
68.51
Vol
945.78K
Mkt Cap
5.33B
Low
67.280
Amount
64.79M
EV/EBITDA(TTM)
25.02
Total Shares
78.63M
EV
6.33B
EV/OCF(TTM)
18.81
P/S(TTM)
2.46
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network over of 435 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis & treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
Show More

Events Timeline

(ET)
2026-06-25
06:30:00
DeepHealth Receives FDA Approval for New Breast Imaging Features
select
2026-06-17 (ET)
2026-06-17
10:30:00
RadNet Shares Drop 8.2% to $51.89
select
2026-04-30 (ET)
2026-04-30
17:20:00
RadNet Forms Joint Venture with Saint Alphonsus Health System
select
2026-04-16 (ET)
2026-04-16
16:10:00
GE HealthCare Expands Collaboration with DeepHealth to Advance AI Mammography Tools
select
2026-03-04 (ET)
2026-03-04
07:20:00
DeepHealth Unveils Clinical AI Solutions to Drive Precision Care
select
2026-03-02 (ET)
2026-03-02
16:20:00
US Stocks Volatile After US-Israel Strikes on Iran
select

News

NASDAQ.COM
8.5
06-25NASDAQ.COM
DeepHealth Receives FDA Clearance for New Breast Suite Features
  • New Functionality Approved: DeepHealth's Breast Suite platform has received FDA 510(k) clearance for its Breast Arterial Calcification (BAC) Assessment feature, which automatically detects arterial calcifications on routine mammograms, potentially serving as an early indicator of cardiovascular disease, thereby enhancing early diagnosis capabilities.
  • Cancer Detection Improvement: The FDA also cleared the prior exam integration for ProFound Pro, allowing automatic comparison of current and previous mammograms to track existing lesions and identify new ones, aimed at improving cancer detection rates and reducing patient recall rates, thus enhancing patient experience.
  • Market Launch Plans: DeepHealth announced that both newly cleared functionalities are now commercially available in the U.S., which is expected to generate new revenue streams for the company and further solidify its market position in health informatics.
  • Positive Stock Reaction: RadNet's stock closed at $58.16 on Wednesday and rose over 1% in pre-market trading on Thursday, reflecting market optimism regarding the new functionalities and their potential commercial value.
Newsfilter
8.5
06-25Newsfilter
DeepHealth Receives FDA Clearance for New Breast Imaging Features
  • New Feature Approval: DeepHealth's Breast Arterial Calcification (BAC) Assessment tool has received FDA 510(k) clearance, enabling automatic identification of breast arterial calcifications during routine mammograms, which serves as an early indicator of cardiovascular disease, likely enhancing screening effectiveness and accuracy.
  • Launch of Mammo Dx: The Mammo Dx, which integrates prior exam data, will allow radiologists to compare changes in breast tissue over time, aiding in the detection of subtle lesions that may go unnoticed in single-exam reads, thereby improving cancer detection rates and reducing false positives.
  • Market Impact: The introduction of these two new functionalities positions DeepHealth's Breast Suite as the most comprehensive breast imaging AI suite in the industry, expected to enhance the company's competitiveness in breast cancer screening and diagnostics, addressing the growing clinical needs.
  • Clinical Validation: The BAC Assessment demonstrated over 90% sensitivity and 88% specificity in clinical testing, and it is set to be widely deployed across RadNet imaging centers, further validating its effectiveness in real-world applications.
NASDAQ.COM
5.0
06-10NASDAQ.COM
DeepHealth Launches AI Reporting Platform for Radiologists
  • Platform Launch: DeepHealth Inc. has officially launched Reporting Pro, a next-generation reporting platform that integrates speech recognition, AI findings, measurements, and quality checks, aimed at enhancing radiologists' efficiency amid rising imaging volumes and worsening workforce shortages.
  • Clinical AI Integration: The platform pulls AI-generated findings and measurements from FDA-cleared and CE-marked DeepHealth and third-party tools directly into structured reports, thereby improving accuracy and consistency in reporting.
  • Rapid Deployment: Reporting Pro supports the migration of existing templates and reporting preferences, allowing radiologists to maintain familiar workflows while adopting AI-enhanced tools, thus minimizing the learning curve and adaptation time.
  • Unified Workflow: By combining speech recognition, AI findings, measurements, impressions, and quality assurance into a single connected reporting environment, Reporting Pro significantly reduces manual steps and data transfer, thereby improving efficiency and clinical quality.
Newsfilter
5.0
06-10Newsfilter
DeepHealth Launches AI Reporting Solution for Radiologists
  • AI Reporting Solution Launch: DeepHealth has introduced Reporting Pro, an AI-integrated reporting tool designed to enhance radiologists' efficiency by automating reporting processes, which is expected to significantly reduce reporting times and directly improve the speed of treatment decisions for patients and physicians.
  • Clinical AI Integration: The platform integrates FDA and CE-marked AI tools, enabling clinically relevant results to flow directly into structured reports, thereby enhancing accuracy and consistency, and helping radiologists work more efficiently in high-demand environments.
  • Rapid Deployment and Adaptation: Reporting Pro supports seamless integration with existing workflows, allowing radiologists to maintain familiar templates and preferences while transitioning to a more intelligent reporting experience, ensuring a smooth technological shift.
  • Market Expansion Plans: The solution is currently commercially available in the U.S. and the U.K., with plans to expand to Australia, South Africa, and select European markets by the end of the year, demonstrating DeepHealth's growth potential in the global radiology market.
seekingalpha
8.5
06-03seekingalpha
RadNet Seeks $200 Million Incremental Term Loan
  • Financing Plan: RadNet is seeking to raise a $200 million incremental term loan through an amendment to its existing first-lien credit agreement, which will be added to the current term loan maturing on April 18, 2031, indicating the company's proactive approach to future funding needs.
  • Use of Proceeds: The company expects to utilize the proceeds for future acquisitions, organic expansion initiatives, health system partnerships, and other general corporate purposes, highlighting its strategic intent for market expansion and business diversification.
  • Market Conditions: RadNet noted that the financing remains subject to customary market and other conditions, reflecting the company's emphasis on risk management during the financing process.
  • Transaction Timeline: If completed, the transaction is expected to close around mid-June, providing the necessary funding support for the company's future growth plans.
Fool
6.5
06-02Fool
Alpha Wave Global Reduces RadNet Stake by 63,147 Shares
  • Stake Reduction Details: According to an SEC filing dated May 14, 2026, Alpha Wave Global reduced its RadNet position by 63,147 shares in Q1, with an estimated trade value of approximately $4.31 million, indicating a cautious outlook on the company.
  • Ownership Proportion Change: Following the reduction, Alpha Wave Global's stake in RadNet stands at 478,304 shares, representing 3.38% of its 13F AUM, reflecting a diminished confidence in the company's future performance.
  • Financial Performance Overview: RadNet's latest earnings report indicates a 22.1% year-over-year revenue increase to $575.6 million, with adjusted EBITDA rising 36.3% to $63.3 million, showcasing strong growth potential in its imaging business.
  • Market Performance Analysis: As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, significantly underperforming the S&P 500 by 38.9 percentage points, prompting investors to closely monitor its future market performance.
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
Wall Street analysts forecast RDNT stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
86.00
Averages
90.17
High
95.00
Current: 0.000
sliders
Low
86.00
Averages
90.17
High
95.00
Barclays
Andrew Mok
Overweight
to
Buy
downgrade
$70 -> $65
AI Analysis
2026-05-20
Reason
Barclays
Andrew Mok
Price Target
$70 -> $65
AI Analysis
2026-05-20
downgrade
Overweight
to
Buy
Reason
Barclays analyst Andrew Mok lowered the firm's price target on RadNet to $65 from $70 and keeps an Overweight rating on the shares. The firm says RadNet is outperforming Lumexa on advanced volume growth and imaging segment pricing.
B. Riley
Buy
downgrade
$87 -> $83
2026-05-01
Reason
B. Riley
Price Target
$87 -> $83
2026-05-01
downgrade
Buy
Reason
B. Riley lowered the firm's price target on RadNet to $83 from $87 and keeps a Buy rating on the shares. The Q1 reports across the radiotherapeutics and imaging agents point to a multi-indication PET volume growth, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RDNT
Unlock Now

Valuation Metrics

The current forward P/E ratio for RadNet Inc (RDNT.O) is 36.63, compared to its 5-year average forward P/E of 81.50. For a more detailed relative valuation and DCF analysis to assess RadNet Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
81.50
Current PE
36.63
Overvalued PE
111.99
Undervalued PE
51.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
18.27
Current EV/EBITDA
81.98
Overvalued EV/EBITDA
28.47
Undervalued EV/EBITDA
8.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.62
Current PS
1.98
Overvalued PS
2.34
Undervalued PS
0.90

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

no which two coins under .01
Intellectia · 347 candidates
Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0
Ticker
Name
Market Cap$
top bottom
PEPE logo
PEPE
Pepe
1.65B
G logo
G
Gravity
56.10M
PUMP logo
PUMP
Pump.fun
716.00M
BONK logo
BONK
Bonk
579.97M
PENGU logo
PENGU
Pudgy Penguins
498.58M
SHIB logo
SHIB
Shiba Inu
3.66B
what Crypto has a higher volume right now
Intellectia · 1019 candidates
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.42T
ETH logo
ETH
Ethereum
251.64B
SOL logo
SOL
Solana
50.14B
NIGHT logo
NIGHT
NIGHT
840.27M
TRUMP logo
TRUMP
OFFICIAL TRUMP
939.99M
XRP logo
XRP
XRP
85.96B
beli apa jual
Intellectia · 483 candidates
Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Macd: bullish
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.43T
ETH logo
ETH
Ethereum
256.28B
BNB logo
BNB
BNB
89.96B
XRP logo
XRP
XRP
86.36B
SOL logo
SOL
Solana
51.59B
TRX logo
TRX
TRON
27.51B
what crypto is active today?
Intellectia · 1016 candidates
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.43T
ETH logo
ETH
Ethereum
251.33B
SOL logo
SOL
Solana
50.94B
USD1 logo
USD1
World Liberty Financial USD
4.60B
XRP logo
XRP
XRP
86.23B
OPN logo
OPN
OPN
71.04M
high risk investments, or crypto
Intellectia · 483 candidates
Turnover 24h: >= 100,000Market Cap: 5.00M - 1000.00M
Ticker
Name
Market Cap$
top bottom
FIGHT logo
FIGHT
FIGHT
48.73M
SKR logo
SKR
SKR
237.08M
ELSA logo
ELSA
ELSA
37.65M
SENT logo
SENT
SENT
220.90M
YZY logo
YZY
YZY MONEY
100.82M
XRD logo
XRD
Radix
43.68M
need only two
Intellectia · 15 candidates
Moving Average Relationship: PriceBelowMA20Month Price Change Pct: <= $0.00Option Sentiments: BearishSupport Resistance Relationship: PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
CM logo
CM
Canadian Imperial Bank of Commerce
84.70B
EFX logo
EFX
Equifax Inc
25.95B
H logo
H
Hyatt Hotels Corp
15.55B
CRBG logo
CRBG
Corebridge Financial Inc
15.17B
CCK logo
CCK
Crown Holdings Inc
11.86B
YMM logo
YMM
Full Truck Alliance Co Ltd
10.30B

Whales Holding RDNT

D
Defiance ETFs, LLC
Holding
RDNT
+31.22%
3M Return
E
Emerald Advisers, LLC
Holding
RDNT
+19.27%
3M Return
H
Hood River Capital Management LLC
Holding
RDNT
+19.09%
3M Return
S
Soros Fund Management LLC
Holding
RDNT
+3.94%
3M Return
V
Van Berkom and Associates Inc.
Holding
RDNT
+3.40%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is RadNet Inc (RDNT) stock price today?

The current price of RDNT is 67.83 USD — it has decreased -1.58

What is RadNet Inc (RDNT)'s business?

RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network over of 435 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis & treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.

What is the price predicton of RDNT Stock?

Wall Street analysts forecast RDNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDNT is90.17 USD with a low forecast of 86.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is RadNet Inc (RDNT)'s revenue for the last quarter?

RadNet Inc revenue for the last quarter amounts to 575.63M USD, increased 22.11

What is RadNet Inc (RDNT)'s earnings per share (EPS) for the last quarter?

RadNet Inc. EPS for the last quarter amounts to -0.43 USD, decreased -15.69

How many employees does RadNet Inc (RDNT). have?

RadNet Inc (RDNT) has 8844 emplpoyees as of July 08 2026.

What is RadNet Inc (RDNT) market cap?

Today RDNT has the market capitalization of 5.33B USD.